the limiting component is typically GHK-Cu, where loss of the blue Cu(II) chromophore is a useful visual indicator of concentration drift
The Wolverine protocol combines BPC-157 with TB-500 (a synthetic fragment of Thymosin Beta-4) for a two-pronged approach
Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
Treat it the same way youd document any injectable treatment, detailed, defensible, and stored securely.
Please review our Terms and Conditions in full before placing an order
Always consult your doctor before giving this medicine to a child